logo
Crowdfunded companies are ‘ghosting' investors. Changing the rules could restore trust

Crowdfunded companies are ‘ghosting' investors. Changing the rules could restore trust

Fast Company3 days ago
Imagine you invest $500 to help a startup get off the ground through investment crowdfunding. The pitch is slick, the platform feels trustworthy, and the company quickly raises its target amount from hundreds of people just like you. Then—silence. No updates, no financials, not even a thank-you.
You've been ghosted—not by a friend, but by a company you helped fund.
This isn't just an unlucky anecdote. It's happening across the United States. And while it may violate federal law, there's little enforcement—and virtually no consequences.
Thanks to a 2012 law, startups can raise up to $5 million per year from the general public through online platforms such as Wefunder or StartEngine. The law was intended to 'democratize' investing and give regular people, not just the wealthy, a chance to back promising young companies.
But there's a catch: Companies that raise money this way are required to file an annual report with the U.S. Securities and Exchange Commission and post it publicly. This report, intended to show whether the business is making progress and how it is using investor funds, is a cornerstone of accountability in the system.
As a professor of business law, I wrote the book on investment crowdfunding. And in my recent research, I found that a majority of crowdfunded companies simply ignore this rule. They raise the money and go silent, leaving investors in the dark.
In most cases, I suspect their silence isn't part of an elaborate con. More likely, the founders never realized they had to file, forgot about the requirement amid the chaos of running a young business, or shut down entirely. But whether it's innocent oversight or deliberate avoidance, the effect on investors is the same: no information, no accountability.
This kind of vanishing act would be unthinkable for public companies listed on the stock market. But in the world of investment crowdfunding, limited oversight means that going silent, whatever the reason, is all too easy.
It's not just 1 or 2 victims
When startups go dark, they don't just leave their investors behind—they undermine the entire crowdfunding model.
Investment crowdfunding was meant to be an accessible, transparent way to support innovation. But when companies ghost their backers, the relationship starts to look less like an investment and more like a donation.
It's not just unethical—it's illegal. Federal law requires at least one annual update. But so far, enforcement has been almost nonexistent.
Concerned state attorneys general have encouraged the SEC to ramp up enforcement actions. This could work in theory, but it's unrealistic in practice, given the SEC's limited resources and broad mission.
If nothing changes, the crowdfunding experiment could collapse under the weight of mistrust.
Incentives work—let's use them
Fortunately, there's a low-cost solution.
I propose that crowdfunding platforms hold back 1% of the capital raised until the company files its first required report. If it complies, it gets the funds. If not, it doesn't.
It's a small but powerful incentive that could nudge companies into doing the right thing, without adding bureaucratic complexity.
It's the same principle used in escrow arrangements, which are common in finance. In a home sale, for example, part of the money goes into a neutral holding account—escrow—until the seller meets certain agreed conditions. Only then is it released. Applying that approach here, a small slice of crowdfunding proceeds would stay in escrow until the company files its first annual report. No report, no release.
Unfortunately, crowdfunding platforms are unlikely to adopt this voluntarily. They compete with one another for deal flow, and any rule that makes fundraising slightly harder at one platform could send startups to a rival site.
However, the SEC has the legal authority to update its rules, and this change would be easy to implement—no new laws, no congressional fights, just a bit of regulatory will. I've even drafted a proposed rule, ready-made for the SEC to adopt, and published it in my recent article, 'Ghosting the Crowd.'
The idea behind investment crowdfunding remains powerful: Open the door to entrepreneurship and investment for everyone. But if that door leads to silence and broken promises, trust will disappear—and with it, a promising financial innovation.
A tiny tweak to the rules could restore that trust. Without it, investors will keep getting ghosted. And the market might ghost them right back.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Masimo sues US Customs over approval of Apple Watch imports
Masimo sues US Customs over approval of Apple Watch imports

Yahoo

time6 minutes ago

  • Yahoo

Masimo sues US Customs over approval of Apple Watch imports

By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Medtronic Stock Raced Higher Today
Why Medtronic Stock Raced Higher Today

Yahoo

time6 minutes ago

  • Yahoo

Why Medtronic Stock Raced Higher Today

Key Points Investors traded out of the company the previous day following its latest earnings release. The stock came roaring back on Hump Day, however. 10 stocks we like better than Medtronic › A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (SNPINDEX: ^GSPC) 0.2% drop. Healthy raises Following a trend that began Tuesday after Medtronic published its first quarter of fiscal 2026 figures. The company posted revenue growth of 8% (to almost $8.6 billion), and improved non-GAAP (generally accepted accounting principles) adjusted net income by 2% to slightly over $1.6 billion. Both headline numbers beat the consensus analyst estimates, albeit not by much. The market, which collectively loves a crushing beat on analyst estimates, basically shrugged at this. Many investors traded out of Medtronic that day. The sun was shining brighter on Wednesday thanks to that series of price target bumps. By my count, seven analysts tracking the stock upped their fair-value assessments. Among these were pundits at such financial industry heavyweights as Wells Fargo, J.P. Morgan, and international bank UBS. Positive moves from cautious pundits I should note that in all cases, those price target raises were incremental. Nevertheless, the raising analysts frequently sounded bullish notes on Medtronic's prospects. One example was Leerink Partners' Mike Kratky, who only added $1 per share for a new level of $111, but maintained his outperform (read: buy) recommendation. According to reports, Kratky praised several elements of the company's operations, particularly its cardiac ablation solutions unit. Less positively, the analyst wrote that Medtronic suffered from weakness in its domestic sales. Should you invest $1,000 in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Why Medtronic Stock Raced Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store